Meeting
2024 ASCO Gastrointestinal Cancers Symposium
A phase Ib/II study of atezolizumab plus tivozanib in pancreatic, gallbladder, and bile duct malignancies.
Authors
Brian Hemendra Ramnaraign
University of Florida/UF Health Cancer Center, Gainesville, FL
Brian Hemendra Ramnaraign , Ji-Hyun Lee , Ilyas Sahin , Sherise C. Rogers , Ryan M. Thomas , Carmen J. Allegra , David L. DeRemer , Thomas J. George , Jonathan Alexander Chatzkel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05000294
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr TPS715)
DOI
10.1200/JCO.2024.42.3_suppl.TPS715
Abstract #
TPS715
Poster Bd #
Q4
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase Ib/II study of atezolizumab plus tivozanib in pancreatic, gallbladder, and bile duct malignancies.
First Author: Brian Hemendra Ramnaraign
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrate-resistant prostate cancer and certain other immunologically cold tumors.
First Author: Jonathan Alexander Chatzkel
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrate-resistant prostate cancer and certain other immunologically cold tumors.
First Author: Jonathan Alexander Chatzkel
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrate-resistant prostate cancer and certain other immunologically cold tumors.
First Author: Jonathan Alexander Chatzkel